Lexeo Therapeutics Overview
Lexeo Therapeutics (LXEO) has a ROE of -37.8%, below the sector sector average of -4.47%.
Get informed when a big investor buys or sells
+ Follow-37.80%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Lexeo Therapeutics (LXEO) currently reports a ROE of -37.8%. That is below the sector sector average of -4.47%. Use the charts on this page to explore Lexeo Therapeutics's ROE history and peer comparisons.
Lexeo Therapeutics's ROE of -37.8% is lower than the its sector sector average of -4.47%. That is roughly 745.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Lexeo Therapeutics's current -37.8% should be judged against industry norms (sector average: -4.47%) and against LXEO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -37.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.47%. From there, open related valuation or income-statement pages for Lexeo Therapeutics, and consider following LXEO for alerts when major investors trade the stock.
